The aromatase inhibitors in early breast cancer: Who, when, and why?

Medical Journal of Australia

Volumn 183, Issue 1, 2005, Pages 24-27

  Nordman, Ilona C ^a   Spillane, Andrew J ^a   Hamilton, Anne L ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; SEX HORMONE; TAMOXIFEN;

ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CATARACT; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENZYME INHIBITION; ENZYME SYNTHESIS; FEMALE; FRACTURE; HEART DISEASE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; LUNG EMBOLISM; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN EXPRESSION; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; VAGINA BLEEDING; VAGINA DISCHARGE; VASCULAR DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 21844444806     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06882.x     Document Type: Article

References (29)

1. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer survival in Australia 2001. Part 1: National summary statistics. Canberra: Australian Institute of Health and Welfare, 2001.
2. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Molec Biol 2003; 86: 225-230.
3. Lonning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol 1996; 35 Suppl 5: S38-S43.
4. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95: 2006-2016.
5. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
6. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
7. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398.
8. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
9. Tredway DR, Buraglio M, Hemsey G, Denton G. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-close anastrozole in healthy, premenopausal female volunteers. Fertil Steril 2004; 82: 1587-1593.
10. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988; 319: 1681-1692.
11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group. Lancet 2005; 365: 1687-1717.
12. Fisher B, Costantino JF, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nat Cancer Inst 1998; 90: 1371-1388.
13. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793-1802. Epub 2003 Oct 9.
14. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA-17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 2004; 88s: 847.
15. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
16. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
17. Thurlimann B. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Proceedings of the St Gallen Primary Therapy of Early Breast Cancer 2005. Available at: http://www.ibcsg.org/public/documents/pdf/divers/ BIG_1-98_StGallen_2005.pdf (accessed Jun 2005).
18. Jakesz R, Kaufmann M, Gnant M, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Proceedings of the San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2004; 88 (Suppl 1): S7(2).
19. Boccardo F, Rubagotti A, Amoroso D, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Proceedings of the San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2003; 82 (Suppl 1): S6 (3).
20. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
21. Carlson R, Schurman C, Rivera E, et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2004; 88 (Suppl 1): S237 (6052).
22. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353.
23. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002; 25: 235-237.
24. Clinical practice guidelines for the management of early breast cancer. 2nd ed. Canberra: National Health and Medical Research Council, 2001.
25. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
26. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Nat Cancer Inst 2003; 95: 1758-1764.
27. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997; 15: 969-973.
28. Seeman E, Eisman JA. 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust 2004; 180: 298-303.
29. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003; 21: 3588-3593.